[ad_1] SHANGHAI, Dec. 9, 2025 /PRNewswire/ — D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round. […]
[ad_1] SHANGHAI, Dec. 9, 2025 /PRNewswire/ — D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round. […]